These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24671104)

  • 21. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
    Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
    Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting HDL-cholesterol to reduce residual cardiovascular risk.
    Iacob AO; Choudhury RP
    Curr Opin Lipidol; 2012 Apr; 23(2):172-4. PubMed ID: 22418577
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA approves a statin therapy for some: certain, asymptomatic individuals targeted.
    Mitka M
    JAMA; 2010 Apr; 303(13):1242-3. PubMed ID: 20371776
    [No Abstract]   [Full Text] [Related]  

  • 24. Body mass index and health-related quality of life in apparently healthy individuals.
    Korhonen PE; Seppälä T; Järvenpää S; Kautiainen H
    Qual Life Res; 2014 Feb; 23(1):67-74. PubMed ID: 23686578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
    Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
    Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The presence of cardiovascular disease does not modify the weak impact obesity has on health-related quality of life in patients with hip osteoarthritis in the KHOALA cohort.
    Renaudin L; Guillemin F; Pouchot J; Rat AC
    Joint Bone Spine; 2018 Mar; 85(2):233-238. PubMed ID: 28242173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals.
    Kamat SA; Gandhi SK; Davidson M
    Curr Med Res Opin; 2007 May; 23(5):1121-30. PubMed ID: 17519079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.
    Novack V; MacFadyen J; Malhotra A; Almog Y; Glynn RJ; Ridker PM
    CMAJ; 2012 Apr; 184(7):E367-72. PubMed ID: 22431901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of rosuvastatin in the management of dyslipidemia.
    Rubba P; Marotta G; Gentile M
    Vasc Health Risk Manag; 2009; 5(1):343-52. PubMed ID: 19436657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
    Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
    De Hert M; Kalnicka D; van Winkel R; Wampers M; Hanssens L; Van Eyck D; Scheen A; Peuskens J
    J Clin Psychiatry; 2006 Dec; 67(12):1889-96. PubMed ID: 17194266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosuvastatin for cardiovascular prevention: too many uncertainties.
    Prescrire Int; 2009 Aug; 18(102):176. PubMed ID: 19746571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging.
    Miyauchi K; Takaya N; Hirose T; Ikeda F; Kawamori R; Ohishi H; Yoshida K; Yamamoto M; Arai H; Urabe T; Hattori N; Suzuki M; Maehara T; Sase K; Hatsukami TS; Yuan C; Daida H
    Circ J; 2009 Jan; 73(1):111-5. PubMed ID: 19057091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy.
    Everett BM; Zeller T; Glynn RJ; Ridker PM; Blankenberg S
    Circulation; 2015 May; 131(21):1851-60. PubMed ID: 25825410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of rosuvastatin in Taiwanese patients.
    Chiang CE; Huang SS; Sung SH
    J Chin Med Assoc; 2008 Mar; 71(3):113-8. PubMed ID: 18364261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percent weight reduction required to achieve minimal clinically important improvements in health-related quality of life among African Americans: A secondary analysis of the fit body and soul study.
    Garvin JT; Williams LB; Joshua TV; Looney SW; Marion LN
    Appl Nurs Res; 2017 Aug; 36():100-105. PubMed ID: 28720228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.